In the concluding ii weeks, I bring started writing most epic autumn of Valeant as well as the unraveling of the Theranos story, but I bring held dorsum because all iii stories bring to live on laid upward against the backdrop of the changing wellness tending business. While at that topographic point are numerous stories beingness told most how this is changing, I decided that it made feel to get past times looking at the evolution of the wellness tending draw of piece of job concern over the concluding 25 years and how changes inwards its inwardness characteristics may explicate all iii stories.
The Story
To empathise the drug business, I went dorsum to 1991, towards the starting fourth dimension of a surge inwards spending inwards the U.S. on wellness care. The pharmaceutical companies at the fourth dimension were cash machines, built on a platform of substantial upward front end investments inwards enquiry as well as development. The drugs generated past times R&D that made it through FDA approving as well as into commercial production were used to comprehend the aggregated cost of R&D as well as to generate important excess profits. The commutation to this procedure was the pricing mightiness enjoyed past times the drug companies, the outcome of a well-defended patent system, important increment inwards wellness tending spending, splintered wellness insurance companies as well as lack of accountability for costs at every degree (from patients to hospitals to the government). In this model, non surprisingly, investors rewarded pharmaceutical companies based on the amounts they spent on R&D (secure inwards their belief that the costs could live on passed on to customers) as well as the fullness as well as residual of their production pipelines.
So, how has the story changed over the concluding decade? The rising inwards wellness tending costs seems to bring slowed downwards as well as the pricing mightiness of drug companies has waned for many reasons, amongst Obamacare beingness solely i of many drivers. First, nosotros bring seen more consolidation inside the wellness insurance business, potentially increasing their bargaining mightiness amongst the pharmaceutical companies on drug prices. Second, the regime has used the buying clout of Medicaid to deal for amend prices on drugs, as well as patch Medicare nevertheless industrial plant through insurance companies, it tin lay pressure level on them to negotiate for lower costs. Third, the pharmacies that stand upward for the distribution networks for many drugs bring too been corporatized as well as consolidated, as well as are gaining a vox inwards the pricing process. The internet effect of all of these changes is that R&D has much to a greater extent than uncertain payoffs as well as has to evaluated similar whatever other large uppercase investment, that it is goodness solely when it creates value for a business. Consequently, investors bring had to transcend to a greater extent than measured inwards their judgment of R&D spending at drug companies, rewarding companies for spending to a greater extent than on R&D solely if it is productive as well as punishing them when it is not.
The diminished pricing mightiness story is non a novel i as well as others bring made the points that I bring but it is nevertheless but a story. The existent enquiry is whether the numbers dorsum the story as well as to respond that question, I looked at commutation operating metrics for publicly traded drug companies from 1991 to 2014, amongst the intent of eking out trends inwards the numbers.
The Revenue Growth Story: The Rise of Biotech
The increment inwards wellness tending costs continued into the concluding decade, albeit at levels much to a greater extent than moderate than inwards the 1990s, but the large story was the rising of biotechnology companies inwards the space. At inception, the distinction betwixt pharmaceutical as well as biotech companies wass the method past times which they produced drugs, amongst pharmaceutical firms working amongst chemicals as well as biotechnology companies using alive organisms (bacteria, cells or yeast) to generate their drugs. Given that both R&D processes are designed to generate drugs that transcend through similar FDA approving processes as well as teach sold through the same distribution channels, this departure is i that solely scientists tin relate to, as well as i that is becoming meaningless every bit R&D departments at both groups poach on the other's territory. The repose of the differences that people request to betwixt the two, i.e, that biotech companies pass to a greater extent than fourth dimension on research, tend to lose coin as well as are riskier than pharmaceutical firms bring less to arrive at amongst draw of piece of job concern differences than life cycle differences.
In the painting demo below, I human face at the aggregate revenues reported past times pharmaceutical as well as biotechnology companies from 1991 to 2014.
 |
| Source: Classification past times S&P Capital IQ |
Note that past times the concluding decade, as well as peculiarly since 2010, almost all of the increment inwards the drug draw of piece of job concern has come upward from the biotech companies, amongst pharmaceutical companies reporting apartment revenues betwixt 2010 as well as 2014. In 2014, biotech companies accounted for 30.63% of total revenues at drug companies, upward from 19.23% inwards 2010.
As amongst every scandal, I am certain that in that location volition live novel revelations as well as intelligence stories inward the calendar week ahead, around pointing to accounting problems, around to work organisation model failures as well as around to legal jeopardy. Even if Valeant emerges unscathed legally from this mess, I only don’t run into how they tin revert to their onetime work organisation model, as well as it is non clear to me that without it, they are anything to a greater extent than than a middling pharmaceutical company.
The Bottom Line
Does the imminent collapse of Valeant's heart as well as soul work organisation model imply that I grip amongst the brusk sellers who receive got used the Enron analogy to fence that this fellowship is a trounce worth nothing? No, as well as hither is why. Unlike Enron, a fellowship that used special operate entities as well as complex holdings to enshroud it debt as well as had no assets amongst tangible value at the fourth dimension of its troubles, Valeant chemist's shop holdings seem designed to a greater extent than for pricing ability than accounting sleight of manus as well as it owns assets that receive got existent value. Thus, fifty-fifty if Valeant's capacity to grow productively is removed tomorrow, it volition even as well as so receive got value every bit a going concern or every bit a collection of assets.
Going concern value
If Valeant is able to move far through its troubles intact, ane selection that is available to it is to larn a to a greater extent than conventional drug company, resting on R&D for (low) growth as well as making coin of its established products. To value Valeant inward this scenario, hither are the assumptions that I made:
Given my perspective on the company, as well as it is undoubtedly flawed, I don't run into Valeant every bit a significantly nether valued stock, inward spite of the toll drib over the final few weeks. I also don't run into it every bit bubble waiting to burst, a stock heading towards beingness worth nothing. For the moment, I mean value volition sit down on the sidelines as well as watch.
- Base twelvemonth earnings: One of the positive effects of suspending an acquisition-driven strategy is that the expenses associated amongst acquisitions should also dissipate. Consequently, I added dorsum acquisition-related expenses (impairment of goodwill, acquisition charges) to operating income to larn to an adjusted operating income for the final twelve months. (Update: As around of yous receive got pointed out, the most twelve months of financials include only half-dozen months that include Salix as well as thus understate revenues as well as operating income. To remedy this, I require to select inward Salix's revenues as well as operating income from the last quarter of 2014 as well as the outset quarter of 2015 into my trailing numbers. Unfortunately, Salix did non file a first quarter earnings written report for this year, but hither is an approximation. In 2014, Salix generated $1.134 billion inward revenues but reported an operating loss. If yous assume that revenues come upwardly inward evenly over the twelvemonth as well as yous allow for the operating margin of 25.51% that Salix earned inward 2012 & 2013, yous larn revenues of well-nigh $567 1000000 and operating income of $145 1000000 for the missing quarters. Adding these to the trailing 12 calendar month numbers increases the value per portion to $77. H5N1 to a greater extent than optimistic take, where Valeant is able to earn its higher operating margin increases the value per portion to $81. The bottom line is that bringing inward Salix's bump to revenues as well as operating income, which is probable to create growth inward the side past times side twelve months, pushes upwardly value per portion but non past times plenty to alter my basic conclusion, which is that the stock is, at best, fairly valued.)
- Pricing backlash: I assumed that the contention over Valeant's drug pricing strategy volition termination inward curlicue backs of toll increases on around of its drugs, resulting inward a permanent drib of 10% inward earnings. (Update: Though this pose out seems to come upwardly out of left champaign (and it is subjective), it comes from lowering Valeant's pre-tax operating margin (prior to adjustments) of 28.3% towards that of other drug companies which is 25.5%; the drib of 2.8% is roughly the 10% drop. I am also assuming that in ane lawsuit the losses from prior acquisitions curlicue off, the taxation charge per unit of measurement volition motility upwardly to 20%, lower than the tax rate paid past times United States of America pharmaceutical companies, reflecting the company's Canadian base.)
- Low growth: If Valeant follows the measure pharmaceutical fellowship exercise of investing inward R&D as well as hoping for payoffs, its expected growth charge per unit of measurement volition drib to anemic levels (as suggested past times my final ship service on drug companies). I volition assume a 3% growth charge per unit of measurement inward earnings for the side past times side 10 years, good below the 20% posted past times Valeant over the final 5 years, but much of that growth was acquired. (Update: I know that management is forecasting 10% from organic growth. That may really good live truthful for side past times side year, every bit the Salix bump kicks in, but it is tough to sustain thereafter, amongst substantially increasing R&D.)
- R&D spending: I volition assume that Valeant volition receive got to invest inward R&D to hold this growth going, as well as inward my valuation, that investment volition reverberate the provide on working capital alphabetic quality of 15.25% that I receive got estimated for the fellowship (with the adjusted earnings).
- Cost of capital: Factoring inward both the expert side of Valeant's high debt ratio (the taxation effected cost of debt) as well as the bad side (higher cost of debt as well as equity) as well as the revenue exposure for Valeant (75% from developed markets, 25% from emerging markets), I guess a cost of working capital alphabetic quality of 7.52%.
 |
| Spreadsheet amongst valuation |
Sum of the parts
If this scandal has legs as well as non only lingers, but creates legal problems that taint Valeant every bit a corporation, in that location is a 2nd option. Just every bit Valeant’s ascent inward value was built on additions, yous could create a contrary strategy where value is generated past times subtraction. Thus, Valeant could sell itself slice past times slice (drugs as well as divisions) to the highest bidders, since each slice volition live worth to a greater extent than to an untainted buyer than it would live worth to Valeant. If this is the optimal path, it volition live interesting to run into if this squad that has built the fellowship upwardly over the final v years is willing to prepare aside hubris as well as intermission it downwards over the side past times side few years.
The Bottom Line
The Valeant story reinforces many of my existing biases against companies that grow primarily through acquisitions. I am willing to concede that this strategy tin pay off, if companies maintain discipline, but my sense amongst these companies is that they inevitably hitting a wall, either because they larn likewise large to rest disciplined or because the accounting creates likewise many opportunities to obfuscate as well as enshroud problems. While Valeant's attempt at creating a novel model for a drug work organisation may receive got failed, that does non brand the existing drug fellowship model a success either. The search has to move on!
YouTube Version
Blog posts inward this series
Spreadsheets
The Bottom Line
The Valeant story reinforces many of my existing biases against companies that grow primarily through acquisitions. I am willing to concede that this strategy tin pay off, if companies maintain discipline, but my sense amongst these companies is that they inevitably hitting a wall, either because they larn likewise large to rest disciplined or because the accounting creates likewise many opportunities to obfuscate as well as enshroud problems. While Valeant's attempt at creating a novel model for a drug work organisation may receive got failed, that does non brand the existing drug fellowship model a success either. The search has to move on!
YouTube Version
Blog posts inward this series
Data Attachments
- Valeant 10K as well as 10Q
- Valeant historical financials
Spreadsheets
